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Abstract
Background: Microarray diagnostics of tumour samples is based on measurement of prognostic
and/or predictive gene expression profiles. Typically, diagnostic profiles have been developed using
bulk tumour samples with a sufficient amount of tumour cells (usually >50%). Consequentially, a
diagnostic results depends on the minimal percentage of tumour cells within a sample. Currently,
tumour cell percentage is assessed by conventional histopathological review. However, even for
experienced pathologists, such scoring remains subjective and time consuming and can lead to
ambiguous results.
Methods: In this study we investigated whether we could use transcriptional activity of a specific
set of genes instead of histopathological review to identify samples with sufficient tumour cell
content. Genome-wide gene expression measurements were used to develop a transcriptional
gene profile that could accurately assess a sample's tumour cell percentage.
Results: Supervised analysis across 165 breast tumour samples resulted in the identification of a
set of 13 genes which expression correlated with presence of tumour cells. The developed gene
profile showed a high performance (AUC 0.92) for identification of samples that are suitable for
microarray diagnostics. Validation on 238 additional breast tumour samples indicated a robust
performance for correct classification with an overall accuracy of 91 percent and a kappa score of
0.63 (95%CI 0.47–0.73).
Conclusion: The developed 13-gene profile provides an objective tool for assessment whether a
breast cancer sample contains sufficient tumour cells for microarray diagnostics. It will improve the
efficiency and throughput for diagnostic gene expression profiling as it no longer requires
histopathological analysis for initial tumour percentage scoring. Such profile will also be very use
useful for assessment of tumour cell percentage in biopsies where conventional histopathology is
difficult, such as fine needle aspirates.
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Background
Microarray diagnostics of tumour specimens is based on
gene expression measurement of a specific set of predic-
tive or prognostic genes. Bulk tumour samples that consist
of tumour cells admixed with surrounding stromal tissue
are commonly used for microarray analysis. Although
tumour stroma likely plays an important role in tumour
development and metastasis [1-3], gene expression pro-
files are typically generated using tissue that contains suf-
ficient amount of tumour cells, not stroma. Most
prognostic gene profiles were originally identified using
samples containing at least 50% tumour cells and are,
therefore, likely based on gene expression of the neoplas-
tic tissue in question. However, some profiles, e.g. Mam-
maPrint [4,5] have been shown to be accurate with 30%
tumour in the diagnostic specimen (AM Glas, unpub-
lished data).
Currently, tumour cell percentage assessment is assessed
using heamatoxilin-eosine (H/E) stained specimen for
histopathological review. However, even for experienced
pathologists, histopathological tumour scoring remains
subjective and time consuming and can lead to inconclu-
sive results [6-8] and variable tumour cell percentage scor-
ing. Moreover, tumour cell scoring can be more difficult
for core biopsies and especially fine-needle aspirates that
are too small or unsuitable for H/E analysis. A tumour
percentage scoring method based on tumour cell mRNA
transcription levels would provide an additional method
to more reliably determine tumour cell content in a
reduced time frame.
Herein we report the development of a molecular profile
that can accurately identify breast cancer samples with suf-
ficient tumour cell content for diagnostic purpose. This
assessment is based on transcription levels and is able to
reduce the time that is needed for a microarray experiment
as no initial pathological tumour cell percentage (TCP)
scoring will be required before sample processing. Moreo-
ver, the identified tumour percentage profile would facili-
tate microarray diagnostics of small specimens for which
tumour sections can not be generated for pathological
scoring.
Methods
Four hundred and three frozen tumour samples or
tumour samples preserved in RNALater from breast cancer
patients were used. At the time of initial diagnosis, all
patients had provided consent in the sense that their
tumour samples could be used for investigational pur-
poses. The study was carried out in accordance with the
ethical standards of the Helsinki Declaration and was
approved by the Medical ethical Board of the participating
medical centers and hospitals. All samples were de-identi-
fied, analyzed anonymously and were part of research
implementation studies for MammaPrint.
Histopathological tumour cell percentage assessment was
done based on (H/E) coloured tumour sections. Gene
expression analysis of breast tumour samples was per-
formed using custom-made Agilent 44K high-density
microarrays according to manufacturer's protocols.
Ninety-five selected samples were hybridised against the
MammaPrint reference pool (MRP) [5] and included sam-
ples with a low (<30%, 27 samples), medium (30–49, 19
samples) and high (≥50%, 49 samples) tumour cell per-
centage (TCP). Microarray slides were scanned using a
Agilent G2565AA scanner and were quantified using Fea-
ture Extraction software (version 9.5, Agilent). Gene
expression log-ratio data was obtained from non-back-
ground subtracted sample/reference signal and was nor-
malised using a lowess global normalisation procedure. A
supervised learning approach, similar to that described in
[4,9], was applied to design a gene expression profile for
the identification of samples with low and high TCP (see
below). Potential inter-pathologist variation in tumour
cell scoring (+/- 10%, based on Figure 1) was taken into
account in the learning model by randomly adjusting the
training TCP during each iteration with -10, 0 or 10 per-
cent.
A 3-fold cross validation (CV) method was used to iden-
tify a gene expression profile (nearest-mean classifier) that
showed a strong association with pathological TCP.
Within each CV loop, two-thirds of the samples were ran-
domly selected as training samples and their TCP was
adjusted randomly by either -10, 0 or +10 percent to rep-
resent pathological variation, as indicated above. For all
genes the association between transcriptional levels and
continuous pathological TCP was determined (Pearson
correlation) and the top 200 genes (100 with positive
association and 100 with negative association) were
selected for inclusion in the classifier model. This proce-
dure was repeated five-hundred times (multiple sampling
approach) and selected genes were ranked according to
their CV performance. To identify the optimal number of
genes to be used in the classifier model, the top-ranked
gene set was gradually expanded and the classifier per-
formance was determined for each gene set size, using
leave-one-out CV and measuring the area under ROC
curve (AUC). Next, within the set of 35 top-ranked genes,
genes were removed that showed a large variation across
an additional set of 70 tumour samples with high (≥50%)
TCP. Twenty-two genes that showed a variation in gene
expression greater than 0.4 (stdev across 70 samples) were
excluded from further analysis. This stringent threshold
was used to ensure a stable profile in tumours with a rela-
tive high tumour cell percentage. The remaining set of 13
genes (Table 1) was used to build a nearest-mean classifierBMC Medical Genomics 2009, 2:52 http://www.biomedcentral.com/1755-8794/2/52
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[9]. Optimal threshold setting and performance on all
training samples (n = 165) were determined using a leave-
one-out CV. The tumour percentage classifier was vali-
dated on 238 independent breast tumour samples.
Biological function analysis was performed using Ingenu-
ity Pathway Analysis (IPA version 6.3, Ingenuity Systems
Inc, Redwood City, CA). Full genome gene expression
measurement of all samples analysed in this study is pub-
licly available at the Gene Expression Omnibus (GEO)
with accession number GSE16201.
Results
Pathological tumour cell percentage related gene 
expression in breast cancer
To determine the variation in histopathological tumour
cell percentage scoring, H/E stained tumour sections were
repeatably analysed in a period of six months by five dif-
ferent pathologists (Figure 1). Although the variation
between pathologists (10–15%) was larger than the varia-
tion observed in repeated scoring over time by the same
pathologist (5–10%), the average variation in tumour cell
percentage scoring was 10 percent (range 0 to 60%). This
observed pathological variation (10%) is taken into
account for classifier development as described in detail
in the materials and methods.
Using 95 breast tumour samples that ranged in tumour
cell content from zero to 85 percent, based on analysis of
HE slides, a tumour percentage gene expression profile
was identified. A 3-fold cross validation (CV) method was
used to identify a gene expression profile (nearest-mean
classifier) that showed a strong association with patholog-
ical TCP. This procedure was repeated five-hundred times
(multiple sampling approach) and genes were ranked
according to their CV performance. The multiple sam-
Variation in histo-pathological tumour percentage scoring Figure 1
Variation in histo-pathological tumour percentage scoring. An identical H/E stained tumour section of two tumours 
(A, T228 and B, T550) was scored multiple times by five different pathologists (coloured lines) during a period of 6 months. 
Box-plots represent the overall pathological variation in TCP scoring for each of the two tumour samples.
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Table 1: Genes used for building a tumour cell percentage associated profile.
Gene ID* Description
AI732974 AI732974 Homo sapiens cDNA clone IMAGE:1473008 3'
AK025430 AK025430 Homo sapiens cDNA FLJ21777 fis, clone HEP00173
AK094860 AK094860 Homo sapiens cDNA FLJ37541 fis, clone BRCAN2026340
ANAPC7 NM_016238 Homo sapiens anaphase promoting complex subunit 7
BC031974 BC031974 Homo sapiens cDNA clone IMAGE:4837645
C17ORF73 ENST00000300458 Homo sapiens mRNA for hypothetical protein FLJ20694 variant, clone: COL06209
HEATR3 NM_182922 Homo sapiens HEAT repeat containing 3
LOC147804 NM_001010856 Homo sapiens hypothetical protein LOC147804
OGT NM_181672 Homo sapiens O-linked N-acetylglucosamine (GlcNAc) transferase
PRR13 NM_001005354 Homo sapiens proline rich 13 (PRR13)
SNAP29 NM_004782 Homo sapiens synaptosomal-associated protein, 29 kDa
CNPY3 AF161347 Homo sapiens HSPC084 mRNA, partial cds
TPM3 NM_152263 Homo sapiens tropomyosin 3 (TPM3)
* ID: Refseq, Genbank or Ensembl identifier.BMC Medical Genomics 2009, 2:52 http://www.biomedcentral.com/1755-8794/2/52
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pling CV performance indicated a strong association of
the selected nearest-mean classifier model with patholog-
ical TCP (R2 = 0.42, P < 0.001, Wilcoxon rank-sum test).
To identify the optimal/minimal number of genes to be
used in the classifier model, the top-ranked gene set was
gradually expanded and the classifier performance (area
under ROC curve, AUC) was determined for each gene set
size.
The classifier showed a strong performance (AUC >0.88)
when at least ten of the identified TCP associated genes
were included in the classifier model (Figure 2A). The
highest performance was reached upon inclusion of the
top 35 genes in the classifier and correctly scored 90 per-
cent of the low TCP (<30%) samples and 93 percent of the
high TCP (≥50%) samples.
Identification of a 13-gene profile for assessment of TCP
Although optimal performance was reached with the
complete set of 35 genes, a substantial number of genes
from the 35-gene set showed a significant single-gene per-
formance (AUC >0.80, 12 genes; AUC >0.80, 15 genes). A
minimal combination of just two random genes from
within the 35-gene set resulted in an AUC of greater than
0.80. This performance increased to >0.85 for random set
of least 5 genes (data not shown).
In a next step to further optimise the classifier, an addi-
tional set of 70 tumour samples was used to select from
the 35 gene set those genes that showed stable expression
in samples with a high tumour percentage. As expected,
genes with a higher expression for high TCP (Figure 2B,
right-side) showed a more stable expression across the 70
additional high TCP samples (Figure 2B, blue bars). The
13 genes with the most stable expression (Table 1), which
were all up-regulated in high versus low TCP (Figure 2B),
were selected to build a robust tumour percentage expres-
sion profile (Figure 2C). The 13-gene classifier showed a
high performance (AUC 0.92) for identification of sam-
ples suitable for microarray diagnostics (Table 2). Use of
the optimal classifier threshold for maximum sensitivity
and specificity resulted in accurate classification of 85 per-
cent of low TCP samples and 93 percent of high TCP sam-
ples (Figure 2D).
Biological function analysis indicated that the 35 TCP
associated gene set was enriched for genes associated with
cancer related processes such as cellular morphology
(MGAT3, AQP1, TPM3, MYLK, SFRP1, NTRK2: p = 1.7e-
3), cell-to-cell signalling (JAM2, LOC338328, OGT, MYLK,
NTRK2,  SNAP29: P = 1.7e-3), cellular movement and
invasion (MGAT3, TPM3, MYLK, SFRP1, NTRK2, CCL15:
P = 1.7e-3) and cellular survival and apoptosis (TPM3,
PRR13, OGT, MYLK, SFRP1: P = 3.6e-5).
Validation of the 13-gene profile on a cohort of 238 breast 
tumour samples
The developed tumour percentage profile was validated
on an independent set of 238 breast tumour samples of
varying tumour cell percentage (range 0–90%). The TCP
distribution across this validation cohort was representa-
tive of typical diagnostic samples. The 13-gene molecular
TCP profile correctly assigned 78, 71 and 95 percent of the
low, medium and high TCP samples as assessed by path-
ological scoring (Figure 3A). The profile showed an over-
all accuracy of 91 percent and a kappa score of 0.63
(95%CI 0.47–0.73) and indicating a strong association
between both methods (Table 2). The profile showed a
false-positive classification rate of 5% (high-TCP samples
classified as low by the profile) and a false-negative classi-
fication of 21% (low-TCP samples classified as high by the
profile).
Analysis of continuous TCP profile index and continuous
pathological tumour cell percentage scoring resulted in a
significant association between both methods (R2 = 0.48,
Wilcoxon P < 0.001, AUC 0.90) and indicated that the
profile might also be useful for indication of accurate
tumour cell percentage instead of a low-, medium- or
high-TCP classification. Statistical analysis of the profile
indexes indicated a significant difference in outcome
between samples with a low and medium TCP (P = 0.01,
Student's T-test) and between samples with a low and
high TCP (P < 0.0001) (Figure 3B). Although the differ-
ence in index between medium and high TCP samples
was borderline significant (P = 0.02), the majority of
medium TCP samples (78%) were classified as high TCP
by the molecular profile. This result indicates that both
medium and high TCP harbour a different tumour cell
related gene profile compared to low TCP samples. The
validation results confirm that the molecular profile can
accurately determine samples with a sufficient tumour
percentage for microarray diagnostics based on transcrip-
tional analysis of 13 identified genes.
Discussion
This study reports the development of a tumour cell per-
centage (TCP) assessment method for breast cancer sam-
ples based on transcriptional analysis of 13 genes. The 13-
gene molecular profile has been validated on an inde-
pendent cohort of 238 samples and can accurately iden-
tify breast tumour samples with a sufficient number of
tumour cells for microarray diagnostics. Tumour percent-
age scoring based on the molecular profile is identical to
the pathologist scoring for more than 90 percent of all
analysed tumour samples. Although the variation in
pathologist TCP scoring is in agreement with the number
of discrepancies between pathological and molecular pro-
file classification, this inconsistency is likely caused by the
difference between the number of tumour cells present inBMC Medical Genomics 2009, 2:52 http://www.biomedcentral.com/1755-8794/2/52
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Identification of a tumour percentage transcriptional profile Figure 2
Identification of a tumour percentage transcriptional profile. (A) Classifier performance (area under ROC curve) 
using different top-ranked gene set sizes. Performance is given for classification of low (<30%) and high (≥50%) TCP samples. 
(B) Differential gene expression of top 35 ranked genes between low and high TCP samples. Bars represent expression varia-
tion of each gene across 70 high TCP samples. Thirteen most stably differential expressed genes for high TCP are indicated in 
blue. (C) Heat-map of the 13-gene tumour percentage profile for 95 training samples. Samples are ordered according to their 
pathologist scored tumour percentage. (D) Profile outcome for all 165 training samples. Profile indexes are calculated using a 
leave-one-out CV. Tumour samples are grouped according to their tumour percent scoring and ordered according to the pro-
file index. Horizontal dashed line represents the optimal classification threshold.
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a tumour sample and the actual tumour cell specific
mRNA levels. In addition to the known variation and
inconsistency in pathological scoring of tumour slides
(e.g. Figure 1 and [6,7]), Hsu et al. indicated that formalin
fixation of slides can result in tumour cell shrinkage [10]
and can lead to an underestimation of tumour cell con-
tent. Since the TCP profile is based on transcriptional lev-
els of high TCP related gene expression within fresh or
frozen tumour tissue, we believe that the developed gene
profile likely gives a better indication whether a sample is
suitable for microarray diagnostics compared to a patho-
logical tumour cell percentage scoring on formalin-fixed
H/E stained slides.
The utility of the gene profile lies in its capability to iden-
tify tumours with a high percentage of tumour cells com-
pared to tumours with insufficient tumour content for
subsequent microarray diagnostics. Conventional his-
topathological review results in tumour cell percentage
scorings up to 10% increments but is laborious and
requires an experienced (in-house) pathologist. The pro-
file, on the other hand, is able to distinguish samples with
low-, medium- or high-tumour cell content. Although the
Table 2: Tumour cell percentage profile (TCP) performance.
Median TCP profile index P-value Accuracy
Training cohorts (n = 165)
low pathological TCP (<30%) -0.592 85%
medium/high pathological TCP (≥30%) 0.327 P < 0.0001 88%
Kappa score: 0.68 (95% 0.50 – 0.72)
Validation cohort (n = 238)
low pathological TCP (<30%) -0.589 78%
medium/high pathological TCP (≥30%) 0.305 P < 0.0001 93%
Kappa score: 0.63 (95%CI 0.47–0.73)
P-value, Student's T-test; TCP Accuracy, accuracy between TCP profile assessment and pathological scoring.
Validation of the 13-gene tumour percentage profile on 238 independent samples Figure 3
Validation of the 13-gene tumour percentage profile on 238 independent samples. (A) Profile outcome for 238 
independent validation samples. Tumour samples are grouped according to their pathological scoring and ordered according to 
the profile index. Horizontal line represents the classification threshold that has been determined on the training cohort. (B) 
Box-plots and statistical differences in profiles indexes between the pathological low, medium and high TCP groups. Colours 
similar as in A.
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13-gene profile provides a more qualitative measurement
compared to the quantitative pathological assessment, it
is a value tool for an objective TCP scoring based on tran-
scriptional levels that can quickly identify samples suita-
ble for diagnostics.
Since the gene profile was developed in such a way to
mimic a pathological scoring which has been described as
inconsistent and subjective, one might argue that the TCP
profile also suffers from these factors. The main goal of
this study, however, was not to develop a more accurate
tool for TCP assessment but an objective method that can
be performed independent of pathological expertise and
which is based on transcriptional gene levels instead of
the number of tumour cells. The use of a robust cross val-
idation procedure that included a mimicked pathological
variation was therefore included in the selection model
that should, in principle, select a set of genes that are
robust to this variation. Nevertheless, the 10 percent mis-
classification between the gene profile and pathological
scoring might partly be attributed to this phenomenon.
Future application of the developed TCP profile could sig-
nificantly improve the throughput of microarray diagnos-
tics. Currently, after sample arrival, RNA processing and
expression analysis cannot proceed until a histopatholog-
ical TCP analysis confirms that the tumour sample con-
tains sufficient tumour cells for analysis. As indicated
above, pathological analysis will remain necessary for
detection of ductal carcinoma in situ, necrosis and a
detailed assessment about the percentage of tumour cells
to define the suitability of the specimen. However,
replacement of initial pathologist TCP scoring by a faster
transcription based analysis that is able to identify
whether a sample likely contains sufficient tumour tissue
will shorten the processing time for microarray diagnos-
tics. More importantly, the 13-gene molecular profile for
tumour cell percentage (TCP) enables gene expression
diagnostics for small samples or those on which no H/E
evaluation is possible.
While gene expression profiles tend to be more robust
with inclusion of a larger set of genes [9], we decided to
limit the developed profile to a relatively small number of
genes with optimal performance. The rationale behind
this strategy was that transcriptional TCP assessment is
preferably done before diagnostic microarray analysis as
this assessment will indicate whether a sample is qualified
for gene expression profiling. Future development of the
13-gene molecular profile into a RT-qPCR based assay,
will allow a less subjective qualification of breast tumour
samples as suitable for microarray diagnostics. This way,
only samples with a sufficient TCP will be used for micro-
array diagnostics, saving time, money, and eliminating
the need for a pathologist to score TCP on qualified spec-
imens.
Conclusion
Whether one uses a qPCR assay for specimen selection or
uses parallel microarray readout for final approval, the
developed 13-gene TCP profile will provide an additional
tool for objective assessment of sufficient tumour cell con-
tent in breast cancer tissue. It will improve the efficiency
and throughput for diagnostic gene expression profiling
as it eliminates the need for histopathological analysis in
initial tumour percentage scoring. Moreover, it will also
allows likely qualify small clinical samples, such as fine-
needle aspirates, for transcriptional diagnostics.
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